Sun Pharmaceutical Industries fell 3.79% to Rs 651 at 11:42 IST on BSE on reports that the US drug regulator issued six observations to the company's Halol plant for inspection in August 2018.
Meanwhile, the S&P BSE Sensex was up 47.57 points, or 0.12% to 38,290.38.On the BSE, 5.85 lakh shares were traded in the counter so far compared with average daily volumes of 4.88 lakh shares in the past two weeks. The stock had hit a high of Rs 658 and a low of Rs 640.95 so far during the day. The stock hit a 52-week high of Rs 678.80 on 6 September 2018. The stock hit a 52-week low of Rs 434.80 on 22 May 2018.
On a consolidated basis, Sun Pharmaceutical Industries reported net profit of Rs 1111.06 crore in Q1 June 2018 as compared with net loss of Rs 322.60 crore in Q1 June 2017. Net sales rose 15.76% to Rs 7138.83 crore in Q1 June 2018 over Q1 June 2017.
Sun Pharmaceutical Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
